COAG
Hemab Therapeutics Holdings, Inc. Common Stock
Nasdaq · usd
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades at $37.95 (-2.84%) as of 4:02:06 AM EST on Nov 19, 2026, +14.57% over the past month. Market cap is $1.83B, with 7.3 days to cover in short interest.
Stock performance
How Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.23%
- 1W
- -0.46%
- 1M
- +14.57%
- YTD
- +15.15%
- 1Y
- +15.15%
- 52-wk range
- $23.00 – $55.42
Key statistics
Today's trading snapshot for COAG: day range, open, previous close, volume and market cap.
- Day range
- $38.61 – $40.28
- Open
- $39.30
- Prev close
- $39.06
- Volume
- 301.26K
- Market cap
- $1.83B
- Shares out
- 46.73M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Hemab Therapeutics Holdings, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 4.26
- P/FCF
- —
- ROE
- -17.3%
- ROA
- -16.8%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Hemab Therapeutics Holdings, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 10, 2026
On November 10, 2026, Hemab Therapeutics Holdings, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2026.
- Executive compensation changeSep 24, 2026
Ms. Walbert will receive annual cash compensation of $40,000 as a member of the Board, additional annual cash compensation of $10,000 as a member of the Audit Committee, annual equity grants in accordance with the non-employee director compensation policy and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings.
- Director departureMay 11, 2026
On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the "Company") of her decision to resign as a member of the Company's board of directors (the "Board"), effective immediately. Dr. Tadvalkar's resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
- Public offeringMay 4, 2026
On May 4, 2026, the Company completed its IPO of 19,262,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,512,500 additional shares of common stock, at a public offering price of $18.00 per share. The gross proceeds to the Company from the IPO were $346.7 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
COAG short interest
How heavily COAG is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.3
- Short interest
- 3.31M
- Avg volume
- 451.96K
As of · reported to FINRA twice monthly.
COAG news
The latest news and headlines about Hemab Therapeutics Holdings, Inc. Common Stock (COAG).
- Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 CongresspositiveGlobeNewswire Inc.· Jul 12, 2026
- Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharespositiveBenzinga· May 4, 2026
Frequently asked questions
What is the Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock price today?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is trading at $37.95 (-2.84% on the day) as of 4:02:06 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Hemab Therapeutics Holdings, Inc. Common Stock?
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII…
What is the short interest in COAG?
As of Oct 30, 2026, COAG has 3.31M shares short and 7.3 days to cover.
What exchange is COAG listed on?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of COAG with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a COAG analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.